The UC Davis Cancer Center Biorepository was created in 2004 to provide quality cancer-related human biospecimens that are procured, stored and annotated using international standards of best practices and protocols that are Office for Human Research Protection (OHRP) compliant. The biorepository functions as a centralized tissue bank that provides all cancer center members with an efficient, high quality, stable, reliable, cost-effective access to cancer-related specimens and histology services.
The specific aims of the Biorepository shared resource are: The primary objectives of the CCB shared resource are to facilitate cancer related research at UC Davis by 1 procuring, preparing, storing and dispersing human cancer-related biospecimens from a centralized cancer center biorepository; 2 providing pathological and clinical annotated data using a secure database (caTissue) 3 ensuring compliance with all mandated regulatory processes (HHS, IRB, HIPAA, SRC) thereby promoting ethical research by UC Davis researchers; 4 providing experienced pathologic consultation to investigators 5 efficiently prioritizing, tracking and dispersing biospecimen requests via a rapid, web-based approval and monitoring process 6 providing Tissue Microarray (TMA) construction and histology services for Cancer Center investigators The long-term objective of the CCSR is to facilitate scientific interactions and enhance scientific productivity by providing well-characterized, high-quality cancer-related specimens with annotated data for clinical and basic science research purposes.
The resource provides tissue in various forms of storage as well as bodily fluids that are used in basic cancer research and in animal models of cancer to improve scientific understanding of tumors, tumor development, and anti-tumor therapies with benefit, ultimately, to how cancer patients are treated and cured of disease.
|Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506|
|Zuo, Yang; Qi, Jinyi; Wang, Guobao (2018) Relative Patlak plot for dynamic PET parametric imaging without the need for early-time input function. Phys Med Biol 63:165004|
|McGee, Heather M; Daly, Megan E; Azghadi, Sohelia et al. (2018) Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 101:1259-1270|
|Klapheke, Amy; Yap, Stanley A; Pan, Kevin et al. (2018) Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. Urol Oncol 36:308.e19-308.e25|
|Pol, Arjan; Renkema, G Herma; Tangerman, Albert et al. (2018) Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause extraoral halitosis. Nat Genet 50:120-129|
|Wang, Yuru; Park, SeHee; Beal, Peter A (2018) Selective Recognition of RNA Substrates by ADAR Deaminase Domains. Biochemistry 57:1640-1651|
|Campbell, Mel; Watanabe, Tadashi; Nakano, Kazushi et al. (2018) KSHV episomes reveal dynamic chromatin loop formation with domain-specific gene regulation. Nat Commun 9:49|
|Vogel Ciernia, Annie; Careaga, Milo; LaSalle, Janine M et al. (2018) Microglia from offspring of dams with allergic asthma exhibit epigenomic alterations in genes dysregulated in autism. Glia 66:505-521|
|Li, Peng-Cheng; Tu, Mei-Juan; Ho, Pui Yan et al. (2018) Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells. Drug Metab Dispos 46:2-10|
|Lucchesi, Christopher A; Zhang, Jin; Ma, Buyong et al. (2018) Disruption of the Rbm38-eIF4E complex with a synthetic peptide Pep8 increases p53 expression. Cancer Res :|
Showing the most recent 10 out of 836 publications